Asian Research Journal of Gynaecology and Obstetrics

Peripartum cardiomyopathy is a rare, potentially life-threatening disorder affecting women in late pregnancy & the postpartum period. In spite of  identification of at-risk demographics, theories on etiology, and new targets of therapy for the entity , it still remains an enigma for obstetricians worldwide. The management of PPCM has been  guideline-based treatment for cardiac failure with reduced ejection fraction. Though many newer studies have reported the efficacy of novel therapies, much more research needs to be done. Here an attempt is being made to review the pathogenesis and diagnosis of  PPCM and discuss some of the newest therapies for this enigmatic entity.